New cognitive test aims to catch Alzheimer's earlier with help from memory nurses
NCT ID NCT07598617
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is creating a new computer-based cognitive assessment to help detect Alzheimer's disease in its earliest stages. Researchers are working with memory nurses and older adults to design the test and a training course for nurses. 120 older adults with memory concerns will take the test, along with a brain scan and blood test, to see how well the assessment works.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a practical cognitive test that memory nurses can use to diagnose early Alzheimer's, speeding up access to treatment.
- What could go wrong
- This is an early-stage study focused on developing and testing the assessment, not on treatment. The test may not prove accurate enough for widespread use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
Sep 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Subjective cognitive decline (SCD) is a research descriptor used to refer to people who believe that their cognitive functioning has deteriorated despite performing in the 'normal' range on objective measures of cognitive functioning. People with SCD are at increased risk of developing dementia, and therefore SCD is considered a potential early clinical manifestation of Alzheimer's disease. Mild Cognitive Impairment (MCI) is a descriptor used to refer to people who report experiencing a decline in cognitive functioning and demonstrate cognitive impairment on objective testing. It is thought to be a transitional phase between normal aging and dementia.
- Ages
-
65 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Recruitment Criteria for Subjective Cognitive Decline and Mild Cognitive Impairment Subjective Cognitive Decline Inclusion Criteria * \>3.38 on IQCODE Self-Report items 1-7 (PROTECT) OR * ≥4 on SCD-Q9 (non-Protect) AND * Age ≥65 years * Onset of SCD within the last 5 years * English as a first language * Normal demographically adjusted performance on standardised cognitive tests * Specific Race and Education (using stratified sampling approach) Exclusion Criteria * Cognitive impairment, i.e., performance ≥1 SD below demographically adjusted norms (PROTECT) OR * ≤17 on the telephone MoCA (non-PROTECT) AND * Lacks mental capacity to consent to research * Diagnosis of dementia * Sensory impairment that cannot be corrected for with sensory aids, e.g., blindness. * Previous neurological injury (stroke, traumatic brain injury, severe epilepsy, brain tumour) * Other neurodegenerative syndrome (e.g., Parkinson's disease, multiple sclerosis, etc) * Diagnosis of learning disability * Severe depression (PHQ-9≥15 OR score ≥1 on PHQ-9 suicide question * Current severe psychiatric disorder (bipolar disorder, schizophrenia, or psychotic disorders) * Current drug or alcohol abuse * Untreated diagnosis of sleep apnoea. Mild Cognitive Impairment Inclusion Criteria * \>3.38 on IQCODE Self-Report items 1-7 (PROTECT) * Cognitive impairment, i.e., performance ≥1 SD below demographically adjusted norms (PROTECT) OR * ≥4 on SCD-Q9 (non-PROTECT) * ≤17 on the telephone MoCA (non-PROTECT) OR * MCI diagnosis according to DSM or ICD-11 criteria through an NHS memory clinic. AND * Age ≥65 years * Onset of SCD within the last 5 years * English as a first language * Specific Race and Education (using stratified sampling approach) Exclusion Criteria * A score of ≥3 on any item on the Instrumental Activities of Daily Living scale, subject to clinical judgement. * Lacks mental capacity to consent to research * Diagnosis of dementia * Sensory impairment that cannot be corrected for with sensory aids, e.g., blindness. * Previous neurological injury (stroke, traumatic brain injury, severe epilepsy, brain tumour) * Other neurodegenerative syndrome (e.g., Parkinson's disease, multiple sclerosis, etc) * Diagnosis of learning disability * Severe depression (PHQ-9≥15 OR score ≥1 on PHQ-9 suicide question * Current severe psychiatric disorder (bipolar disorder, schizophrenia, or psychotic disorders) * Current drug or alcohol abuse * Untreated diagnosis of sleep apnoea.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
North East London NHS Foundation Trust
NOT_YET_RECRUITINGLondon, United Kingdom
-
Research Delivery Team
RECRUITINGExeter, United Kingdom
-
University Hospitals Plymouth NHS Trust
RECRUITINGPlymouth, Devon, Plymouth PL6 8BU, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Alzheimer's vaccine aims to clear amyloid before memory fades
- Your phone might notice Alzheimer's decline before you do
- Gut bacteria may hold clues to memory decline
- A cholesterol drug takes on Alzheimer's before symptoms start
- Could a breath test reveal Parkinson's risk?
- Brain scans and genes may unlock early Alzheimer's detection